Bruce Nudell

In a report published Friday, Credit Suisse analyst Bruce Nudell downgraded the rating on Lumenis Ltd. (NASDAQ: LMNS) from Outperform to Underperform, with a $14 price target, following the announcement that the approval of the sale of the company. The analyst believes that Lumenis is likely to...

Shares of Boston Scientific Corporation (NYSE: BSX) surged more than 3 percent Monday's following news that the company's Watchman device was approved by the U.S. FDA. According to RBC Capital Markets analysts Glenn Novarro, Watchman is a "novel left atrial appendage closure device...

In a report published Tuesday, Credit Suisse analyst Bruce Nudell reiterated an Outperform rating on Thoratec Corporation (NASDAQ: THOR), and raised the price target from $40.00 to $45.00. In the report, Credit Suisse noted, "Given our increased expectations of market growth and THOR share, in part...

In a report published Tuesday, Credit Suisse analyst Bruce Nudell reiterated an Outperform rating on Thoratec Corporation (NASDAQ: THOR), and raised the price target from $35.00 to $40.00. In the report, Credit Suisse noted, "We're adjusting our 4Q14 sales/EPS estimates to $109.4M (-12.8% CC)/$0.25...

In a report published Tuesday, Credit Suisse analyst Bruce Nudell reiterated an Outperform rating on Stryker Corporation (NYSE: SYK), and raised the price target from $90.00 to $100.00. In the report, Credit Suisse noted, “We're updating our 4Q14 sales/EPS estimates to $2.62B (8.6% CC, 5.6% organic...

Volcano Corporation (NASDAQ: VOLC) is unlikely to attract a sweeter deal than the one it agreed to Wednesday with Royal Philips, according to a couple of analysts. Volcano, which makes surgical tools for angioplasty, inked a $1 billion deal with Philips that equals $18 a share and is slated to...

In a report published Tuesday, Credit Suisse analyst Bruce Nudell reiterated an Outperform rating and $150.00 price target on Edwards Lifesciences Corp. (NYSE: EW). In the report, Credit Suisse noted, “We're raising our 2015 transcatheter aortic valve implant (TAVI) sales estimates to $1.06B (22%...

In a report published Wednesday, Credit Suisse analyst Bruce Nudell reiterated an Outperform rating on Medtronic (NYSE: MDT), and raised the price target from $70.00 to $80.00. In the report, Credit Suisse noted, “MDT reported F2Q15 sales/EPS of $4.37B (5.0% CC)/$0.96vs. our $4.30B (4.6% CC)/$0.96...

In a report published Tuesday, Credit Suisse analyst Bruce Nudell upgraded the rating on Thoratec Corporation (NASDAQ: THOR) from Neutral to Outperform, and raised the price target from $27.00 to $35.00. In the report, Credit Suisse noted, “We're maintaining our 2014 THOR estimates but lowering our...

In a report published Monday, Credit Suisse analyst Bruce Nudell upgraded the rating on Volcano Corporation (NASDAQ: VOLC) from Neutral to Outperform, but lowered the price target from $16.00 to $14.00. In the report, Credit Suisse noted, “Our VOLC upgrade is based on 3 factors: 1) the belief that...

In a report published Wednesday, Credit Suisse analyst Bruce Nudell downgraded the rating on Vital Therapies Inc (NASDAQ: VTL) from Outperform to Neutral, but raised the price target from $16.00 to $25.00. In the report, Credit Suisse noted, “VTL shares have increased to $23 from $12 since its IPO...

In a report published Tuesday, Credit Suisse analyst Bruce Nudell upgraded the rating on Medtronic (NYSE: MDT) from Neutral to Outperform, and raised the price target from $66.00 to $70.00. In the report, Credit Suisse noted, “We are upgrading MDT to Outperform (from Neutral) following the planned...

Credit Suisse on Monday upgraded Abbott Laboratories (NYSE: ABT) to Outperform from Neutral following the company's announcement to acquire CFR Pharmaceuticals SA and raised the price target to $46 from $44. Credit Suisse analyst Bruce Nudell says the acquisition, which has an estimated value of $...

In a report published Monday, Credit Suisse analyst Bruce Nudell initiated coverage on Trivascular Technologies (NASDAQ: TRIV) with an Outperform rating and $17.00 price target. In the report, Credit Suisse noted, “TRIV is a relatively new entrant in the $1.2B WW endovascular aortic repair (EVAR)...

In a report published Monday, Credit Suisse analyst Bruce Nudell initiated coverage on Vital Therapies (NASDAQ: VTL) with an Outperform rating and $16.00 price target. In the report, Credit Suisse noted, “VTL is developing a cell-based therapy for the treatment of alcohol-induced acute liver de-...